Cannabinoids in the treatment of glaucoma

Järvinen, Tomi; Pate, David W.; Laine, Krista

doi:10.1016/s0163-7258(02)00259-0

Cited by 131 publications

(97 citation statements)

References 154 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These compounds, also called endocannabinoids, activate cannabinoid receptors CB1 and CB2. Activation of these receptors has been reported to induce several biological effects [4,5] such as relief of pain [6] and anxiety [7], increase of appetite [8] and reduction of intraocular pressure [9]. Additionally, the activation of CB2 receptors is involved in the dampening of inflammation, lowering of blood pressure, and suppression of peripheral pain [10].…”

Section: Introductionmentioning

confidence: 99%

Chiral 3-(4,5-dihydrooxazol-2-yl)phenyl alkylcarbamates as novel FAAH inhibitors: Insight into FAAH enantioselectivity by molecular docking and interaction fields

Myllymäki¹,

Käsnänen

Kataja³

et al. 2009

European Journal of Medicinal Chemistry

View full text Add to dashboard Cite

Fatty acid amide hydrolase (FAAH) and monoglyceride lipase (MGL) are the main enzymes responsible for the hydrolysis of endogenous cannabinoids N-arachidonoylethanolamide (AEA) and 2-arachidonoylglycerol (2-AG), respectively. Phenyl alkylcarbamates are FAAH inhibitors with anxiolytic and analgesic activities in vivo. Herein we present for the first time the synthesis and biological evaluation of a series of chiral 3-(2-oxazoline)-phenyl N-alkylcarbamates as FAAH inhibitors. Furthermore, the structural background of chirality on the FAAH inhibition is explored by analyzing the protein-ligand interactions. Remarkably, 10-fold difference in potency was observed for (R)-and (S)-derivatives of 3-(5-methyl-4,5-dihydrooxazol-2-yl)phenyl cyclohexylcarbamate (6a vs. 6b). Molecular modelling indicated an important interaction between the oxazoline nitrogen and FAAH active site.

show abstract

Section: Introductionmentioning

confidence: 99%

Chiral 3-(4,5-dihydrooxazol-2-yl)phenyl alkylcarbamates as novel FAAH inhibitors: Insight into FAAH enantioselectivity by molecular docking and interaction fields

Myllymäki¹,

Käsnänen

Kataja³

et al. 2009

European Journal of Medicinal Chemistry

View full text Add to dashboard Cite

show abstract

“…The converging evidence supporting their use for not only intraocular pressure but also for their neuroprotective effects has prompted a number recent reviews highlighting their promise for this eye disorder [134][135][136]. Pharmacological and histological studies support the direct role of ocular CB1 receptors in the intra-ocular pressure (IOP) reduction induced by cannabinoids.…”

Section: Glaucomamentioning

confidence: 99%

Cannabis and endocannabinoid modulators: Therapeutic promises and challenges

Grant

Cahn

2005

Clinical Neuroscience Research

View full text Add to dashboard Cite

The discovery that botanical cannabinoids such as delta-9 tetrahydrocannabinol exert some of their effect through binding specific cannabinoid receptor sites has led to the discovery of an endocannabinoid signaling system, which in turn has spurred research into the mechanisms of action and addiction potential of cannabis on the one hand, while opening the possibility of developing novel therapeutic agents on the other. This paper reviews current understanding of CB1, CB2, and other possible cannabinoid receptors, their arachidonic acid derived ligands (e.g. anandamide; 2 arachidonoyl glycerol), and their possible physiological roles. CB1 is heavily represented in the central nervous system, but is found in other tissues as well; CB2 tends to be localized to immune cells. Activation of the endocannabinoid system can result in enhanced or dampened activity in various neural circuits depending on their own state of activation. This suggests that one function of the endocannabinoid system may be to maintain steady state. The therapeutic action of botanical cannabis or of synthetic molecules that are agonists, antagonists, or which may otherwise modify endocannabinoid metabolism and activity indicates they may have promise as neuroprotectants, and may be of value in the treatment of certain types of pain, epilepsy, spasticity, eating disorders, inflammation, and possibly blood pressure control.

show abstract

“…During past years cannabinoids have received considerable attention as potential antiglaucomatous drugs [1]. The intraocular pressure (IOP)-lowering action of Δ 9 -tetrahydrocannabinol (THC), the principal psychoactive component of marijuana, was first reported in 1971 [2].…”

Section: Introductionmentioning

confidence: 99%

“…Accordingly, various cannabinoids including anandamide [20], 2-arachidonylglycerol [21], noladin ether [22], WIN55212-2 [23] and JWH015 [24] were shown to act on trabecular meshwork cells to enhance aqueous humor outflow. In two further studies, cannabinoids have been demonstrated to exhibit an inhibitory action on the migration of TM cells by virtue of CB 1 and/or CB 2 receptor activation [25,26].…”

Section: Introductionmentioning

confidence: 99%

Cyclooxygenase-2 and tissue inhibitor of matrix metalloproteinases-1 confer the antimigratory effect of cannabinoids on human trabecular meshwork cells

Ramer

Hinz

2010

Biochemical Pharmacology

View full text Add to dashboard Cite

To cite this version:Robert Ramer, Burkhard Hinz. Cyclooxygenase-2 AND tissue inhibitor of matrix metalloproteinases-1 confer the antimigratory effect of cannabinoids on human trabecular meshwork cells. Biochemical Pharmacology, Elsevier, 2010, 80 (6) This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 3 ABSTRACTCannabinoids have received considerable attention as potential antiglaucomatous drugs.

show abstract

Cannabinoids in the treatment of glaucoma

Cited by 131 publications

References 154 publications

Chiral 3-(4,5-dihydrooxazol-2-yl)phenyl alkylcarbamates as novel FAAH inhibitors: Insight into FAAH enantioselectivity by molecular docking and interaction fields

Chiral 3-(4,5-dihydrooxazol-2-yl)phenyl alkylcarbamates as novel FAAH inhibitors: Insight into FAAH enantioselectivity by molecular docking and interaction fields

Cannabis and endocannabinoid modulators: Therapeutic promises and challenges

Cyclooxygenase-2 and tissue inhibitor of matrix metalloproteinases-1 confer the antimigratory effect of cannabinoids on human trabecular meshwork cells

Contact Info

Product

Resources

About